BeiGene Pre-Tax Profit Margin 2014-2024 | ONC
Current and historical pre-tax profit margin for BeiGene (ONC) from 2014 to 2024. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue. BeiGene pre-tax profit margin for the three months ending September 30, 2024 was .
BeiGene Pre-Tax Profit Margin Historical Data |
Date |
TTM Revenue |
TTM Pre-Tax Income |
Pre-Tax Margin |
2024-09-30 |
$3.32B |
$-0.80B |
-24.06% |
2024-06-30 |
$3.10B |
$-0.47B |
-15.21% |
2024-03-31 |
$2.76B |
$-0.73B |
-26.50% |
2023-12-31 |
$2.46B |
$-0.83B |
-33.60% |
2023-09-30 |
$2.20B |
$-0.91B |
-41.11% |
2023-06-30 |
$1.81B |
$-1.69B |
-93.10% |
2023-03-31 |
$1.56B |
$-1.88B |
-120.47% |
2022-12-31 |
$1.42B |
$-1.96B |
-138.39% |
2022-09-30 |
$1.25B |
$-2.12B |
-169.22% |
2022-06-30 |
$1.07B |
$-2.00B |
-187.00% |
2022-03-31 |
$0.88B |
$-1.92B |
-219.16% |
2021-12-31 |
$1.18B |
$-1.44B |
-122.36% |
2021-09-30 |
$1.06B |
$-1.33B |
-125.61% |
2021-06-30 |
$0.95B |
$-1.34B |
-141.08% |
2021-03-31 |
$0.86B |
$-1.19B |
-138.24% |
2020-12-31 |
$0.31B |
$-1.62B |
-523.62% |
2020-09-30 |
$0.27B |
$-1.52B |
-569.92% |
2020-06-30 |
$0.23B |
$-1.39B |
-619.11% |
2020-03-31 |
$0.40B |
$-1.14B |
-283.33% |
2019-12-31 |
$0.43B |
$-0.94B |
-220.56% |
2019-09-30 |
$0.43B |
$-0.84B |
-195.12% |
2019-06-30 |
$0.43B |
$-0.67B |
-154.84% |
2019-03-31 |
$0.24B |
$-0.75B |
-306.97% |
2018-12-31 |
$0.20B |
$-0.69B |
-346.73% |
2018-09-30 |
$0.16B |
$-0.51B |
-322.15% |
2018-06-30 |
$0.32B |
$-0.25B |
-77.16% |
2017-09-30 |
$0.22B |
$-0.03B |
-15.45% |
2016-12-31 |
$0.00B |
$-0.12B |
-11900.00% |
2016-03-31 |
$0.01B |
$-0.02B |
-328.57% |
2015-12-31 |
$0.01B |
$-0.01B |
-157.14% |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
MED-BIOMED/GENE |
$17.962B |
$2.459B |
BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.
|